Nyxoah (NASDAQ:NYXH) Stock Price Down 3.1% - Should You Sell?

Key Points

• Nyxoah SA stock price fell by 3.1%, trading at $5.90, with a significant decline in trading volume, down 45% from the average session.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" for Nyxoah, with a target price of $15.00 amidst recent earnings that missed estimates.
• Large investors like Franklin Resources Inc. and Kovack Advisors Inc. have increased their stakes in Nyxoah, indicating continued institutional interest despite current stock performance.

Nyxoah SA (NASDAQ:NYXH - Get Free Report)'s share price fell 3.1% on Thursday . The stock traded as low as $5.88 and last traded at $5.90. 47,336 shares changed hands during trading, a decline of 45% from the average session volume of 86,658 shares. The stock had previously closed at $6.09.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Nyxoah in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $15.00.

Nyxoah Stock Down 3.1%

The stock has a market capitalization of $200.95 million, a price-to-earnings ratio of -2.57 and a beta of 1.53. The business has a fifty day moving average of $5.77 and a 200 day moving average of $6.65. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.63 and a quick ratio of 2.38.

Nyxoah (NASDAQ:NYXH - Get Free Report) last released its quarterly earnings data on Monday, August 18th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). Nyxoah had a negative net margin of 1,541.84% and a negative return on equity of 79.18%. The business had revenue of $1.58 million during the quarter, compared to analyst estimates of $1.33 million. As a group, equities analysts predict that Nyxoah SA will post -1.91 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. lifted its stake in Nyxoah by 0.9% during the second quarter. Franklin Resources Inc. now owns 294,990 shares of the company's stock worth $2,207,000 after purchasing an additional 2,655 shares in the last quarter. Kovack Advisors Inc. lifted its stake in Nyxoah by 148.2% during the second quarter. Kovack Advisors Inc. now owns 57,827 shares of the company's stock worth $433,000 after purchasing an additional 34,532 shares in the last quarter. Shay Capital LLC acquired a new position in Nyxoah during the second quarter worth $374,000. Raymond James Financial Inc. acquired a new position in Nyxoah during the second quarter worth $70,000. Finally, Bank of America Corp DE lifted its stake in Nyxoah by 72.4% during the second quarter. Bank of America Corp DE now owns 7,866 shares of the company's stock worth $59,000 after purchasing an additional 3,303 shares in the last quarter.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.